KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Total Liabilities: 2020-2025

Historic Total Liabilities for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $352.6 million.

  • Recursion Pharmaceuticals' Total Liabilities rose 74.60% to $352.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $352.6 million, marking a year-over-year increase of 74.60%. This contributed to the annual value of $413.8 million for FY2024, which is 117.50% up from last year.
  • Recursion Pharmaceuticals' Total Liabilities amounted to $352.6 million in Q3 2025, which was down 7.99% from $383.2 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Total Liabilities' 5-year high stood at $413.8 million during Q4 2024, with a 5-year trough of $55.9 million in Q2 2021.
  • In the last 3 years, Recursion Pharmaceuticals' Total Liabilities had a median value of $197.7 million in 2023 and averaged $259.0 million.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Total Liabilities spiked by 324.89% in 2022, and later decreased by 20.54% in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' Total Liabilities (Quarterly) stood at $67.4 million in 2021, then surged by 219.67% to $215.5 million in 2022, then fell by 11.70% to $190.3 million in 2023, then soared by 117.50% to $413.8 million in 2024, then spiked by 74.60% to $352.6 million in 2025.
  • Its last three reported values are $352.6 million in Q3 2025, $383.2 million for Q2 2025, and $371.3 million during Q1 2025.